Glucocorticoid-induced osteoporosis

Stuart L. Silverman, Nancy E Lane

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalCurrent Osteoporosis Reports
Issue number1
StatePublished - 2009
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Glucocorticoid-induced osteoporosis'. Together they form a unique fingerprint.

Cite this